OGD/OND system will help share reviews
Executive Summary
The Office of Generic Drugs is adopting a new information technology system that will enable it to share reviews with the Office of New Drugs, allowing both offices "full access to all available information of approved drug products," FDA announces Oct. 6. The new electronic Division File System provides OGD "document management, tracking, archiving, and electronic signature capabilities for internally generated review documents and search and retrieval capabilities for final versions of internally generated documents." FDA hopes the improved electronic repository for ANDA review and regulatory documents will improve the efficiency of the generic review process; OGD's mounting application backlog has come under fire over the last year (1"The Pink Sheet" Feb. 13, 2006, p. 7)...
You may also be interested in...
Generic Drug Reviews Take A Hit In FDA 2007 Budget Request
FDA is reducing the percentage of generic drug applications for which it aims to shorten review time
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.